Results 271 to 280 of about 207,050 (299)

Short-term Prostate-specific Antigen Pseudoregression Following [177Lu]–Prostate-specific Membrane Antigen Therapy

Clinical Nuclear Medicine
A 74-year-old man with metastatic castration-resistant prostate cancer underwent 2 cycles of [177Lu]Lu-prostate-specific membrane antigen (PSMA) therapy. Despite declining prostate-specific antigen (PSA) levels and pain relief throughout the first 4 months of [177Lu]Lu-PSMA therapy, follow-up [68Ga]Ga-PSMA PET/CT revealed progressive skeletal ...
Ahmed Saad Abdlkadir, Nazmi Kamal, Mohannad Badarneh, Akram Al-Ibraheem   +3 more
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

Prostate-specific Membrane Antigen

PET Clinics
Ian L. Alberts, Robert Seifert, Rudolf A. Werner, Steven P. Rowe, Ali Afshar-Oromieh   +4 more
openaire   +2 more sources

Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.

Anticancer research, 1995
PSA (prostate specific antigen) and PSMA (prostate specific membrane antigen) serum levels were determined in over 235 prostate cancer patients from 8 different United States clinical urological cancer centers. The clinical data were not known until after the serum assay results were shared with all participants to attempt to eliminate possible ...
G, Murphy, H, Ragde, G, Kenny, R, Barren, S, Erickson, B, Tjoa, A, Boynton, E, Holmes, J, Gilbaugh, T, Douglas   +9 more
openaire   +1 more source

Overview of prostate-specific membrane antigen.

Reviews in urology, 2011
Efforts to evaluate and discover diagnostic and therapeutic markers for prostate cancer continue. One of these, prostate-specific membrane antigen (PSMA), a transmembrane protein expressed in all types of prostatic tissue, remains a useful diagnostic and possibly therapeutic target.
openaire   +1 more source

Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention

Ca-A Cancer Journal for Clinicians, 2017
Cynthia Morata-Tarifa, Joyce M Slingerland   +1 more
exaly  

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Ca-A Cancer Journal for Clinicians, 2020
Aaron J Grossberg, William L Hwang, Anirban Maitra   +2 more
exaly  

Oral complications of cancer and cancer therapy

Ca-A Cancer Journal for Clinicians, 2012
Joel B Epstein, Rene-Jean Bensadoun, Andrei Barasch   +2 more
exaly  

The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment

Ca-A Cancer Journal for Clinicians, 2018
Pricivel M Carrera, Hagop M Kantarjian, Victoria S Blinder   +2 more
exaly  

American Cancer Society Head and Neck Cancer Survivorship Care Guideline

Ca-A Cancer Journal for Clinicians, 2016
Nader Sadeghi, Katherine A Hutcheson, Gary H Lyman   +2 more
exaly